Medicare to offer Wegovy for obesity at $50/month starting July 2026

Starting July 1, 2026, eligible Medicare patients with obesity can access Wegovy (semaglutide) for a $50 monthly copay through the new Medicare GLP-1 Bridge program. This initiative, in partnership with Novo Nordisk, covers all Wegovy doses and forms nationwide until the end of 2027, expanding access to FDA-approved obesity treatments. Meanwhile, Amazon Pharmacy is enhancing access to the oral Ozempic pill with same-day delivery and in-office pickup options, making diabetes treatment more convenient for insured customers.